Oksana L. Kolobova

Oksana L. Kolobova

Auto-generated profile, based on publicly available information

Oksana L. Kolobova

Saint Petersburg State Pediatric Medical University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2020 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
NBN. M. Bogdanova
N. M. Bogdanova
AKAnatoly Khavkin
Anatoly Khavkin
OKO. L. Kolobova
O. L. Kolobova
Lactose (β-galactosyl-1,4 glucose) is milk sugar, the main disaccharide of human and other mammalian breast milk. Lactase is intestinal disaccharidase that catalyzes the lactose hydrolysis. The lactase gene LCT controls biological function of the enzyme. The age-related genetically determined feature of disaccharide expression, epigenetic factors, and natural selection with persistent tolerance to milk sugar throughout lifetime has divided the human population according to the LCT gene into two phenotypes: lactase persistent and lactase non-persistent. There is conflicting evidence that the latter phenotype is associated with low calcium absorption and the development of osteoporosis. The regular use of fermented probiotic dairy products by individuals with the lactase non-persistence phenotype ensures the accumulation of peak bone mineralization and prevents osteoporosis.

2 December 2018 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
Mikhail KostikMikhail Kostik
Mikhail Kostik
OZOlga V. Zhogova
Olga V. Zhogova
NLNatalia V. Lagunova
Natalia V. Lagunova
SISergey V. Ivanovskiy
Sergey V. Ivanovskiy
OKOksana L. Kolobova
Oksana L. Kolobova
LMLarisa N. Melnikova
Larisa N. Melnikova
Семейная средиземноморская лихорадка: современные подходы к диагностике и лечению

31 January 2019 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
NBNatalia V. Buchinskaya
Natalia V. Buchinskaya
Mikhail KostikMikhail Kostik
Mikhail Kostik
OKOksana L. Kolobova
Oksana L. Kolobova
LMLarisa N. Melnikova
Larisa N. Melnikova
Mucopolysaccharidosis type I (MPS I) is a hereditary metabolic disease that manifests itself in childhood by systemic damage to tissues and organs, a constantly progressive course leading to disability. Diagnosis of mild forms of the disease is particularly difficult due to the absence of specific symptoms. A specific symptom of the mild forms of MPS I (as for other types of MPS) is joint stiffness in children combined with hernia, frequent infections, or valvular defects. Stiffness in MPS I is often interpreted as a manifestation of rheumatological diseases (arthrogriposis, juvenile idiopathic arthritis). The article offers a simple algorithm for diagnosing MPS I, which helps to eliminate the disease using a simple test for determining the activity of an enzyme called alpha-L-iduronidase in a dried blood spot.

2 March 2023 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Closed access
PDF file
EKE. M. Kalashnikova
E. M. Kalashnikova
RRRinat Raupov
Rinat Raupov
NLN. A. Lyubimova
N. A. Lyubimova
EKE. M. Kuchinskaya
E. M. Kuchinskaya
VMV. V. Masalova
V. V. Masalova
Mikhail KostikMikhail Kostik
Mikhail Kostik
Systemic lupus erythematosus is an immunopathological disease which is characterized by a poor prognosis. Biologics applied in the disease treatment allow reducing the corticosteroid toxicity and controlling the disease.Purpose. To evaluate the efficacy and safety of rituximab therapy in children with systemic lupus erythematosus.Material and methods. The retrospective study included data of 48 patients with systemic lupus erythematosus treated with rituximab. Systemic lupus erythematosus was diagnosed based on the SLICC classification criteria. Patients were assessed at baseline disease status, at the time of rituximab initiation and follow-up. The indications for the rituximab were: lupus nephritis, CNS involvement, and hematological involvement resistant to the standard therapy, and in cases of severe corticosteroid toxicity.Results. During rituximab therapy the significant decrease of the SELENA–SLEDAI activity index was observed. There was a significant decrease of the level of antibodies against dsDNA, normalization of the levels of hemoglobin, ESR, complement C4. The proportion of patients with cytopenia decreased up to their complete absence in patients receiving therapy for three years. The number of patients with active lupus nephritis decreased from 16 at the time of rituximab initiation to 1 after 3 years of therapy. Significant dynamics of proteinuria and hematuria was noted, except for 1 patient. The daily dose of corticosteroids was reduced by 90% from baseline in patients treated for 3 years. Serious adverse events included three deaths in patients with high systemic lupus erythematosus activity with uncontrolled macrophage activation syndrome associated with infections. Various infectious complications, hypogammaglobulinemia, which required replacement therapy with intravenous immunoglobulin, were also recorded.Conclusion. Rituximab can be considered as an option for the treatment of severe forms of systemic lupus erythematosus which are resistant to standard therapy. Further studies are required to evaluate efficacy and safety.

13 October 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
EKE.M. Kalashnikova
E.M. Kalashnikova
RRRinat Raupov
Rinat Raupov
VMV.V. Masalova
V.V. Masalova
EIE.A. Isupova
E.A. Isupova
EGE.V. Gaidar
E.V. Gaidar
DIDmitri O. Ivanov
Dmitri O. Ivanov

26 May 2026 in Current Pediatrics
Verified
Journal Article
Closed access
MAMirzonuriddin M. Alimov
Mirzonuriddin M. Alimov
AKAlexandr A. Konstantinov
Alexandr A. Konstantinov
NGNataly O. Grankina
Nataly O. Grankina
ATAlexandr V. Trofimov
Alexandr V. Trofimov
OKOksana L. Kolobova
Oksana L. Kolobova
Mikhail KostikMikhail Kostik
Mikhail Kostik
Hypophosphatasia (HPP) is a monogenic bone disease caused by alkaline phosphatase (ALP) deficiency due to variants in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNALP). This disease is systemic due to numerous ALP functions, and it affects musculoskeletal (bone demineralization with rickets-like changes, stress fractures, arthralgias, enthesopathies, early tooth loss), respiratory (pulmonary hypoplasia), nervous (pyridoxine-dependent seizures, chronic pain syndrome), and urinary systems. HPP diagnosis is based on the repeat measurements of ALP activity and its blood and urine metabolites levels, evaluation of X-ray changes, and revealing ALPL gene variants. The only effective treatment for HPP is enzyme replacement therapy with asfotase alfa. This review covers disease mechanisms, its clinical signs, diagnosis and management methods. Unusual case study of HPP with atypical stress fractures is presented.